Silke Mark

Title: Silke Mark: Innovator in Pharmaceutical Formulations for Spinal Fusion

Introduction

Silke Mark is a notable inventor based in Brugg, Switzerland. She has made significant contributions to the field of pharmaceutical formulations, particularly in spinal fusion methods. Her innovative work has led to the development of a unique formulation that enhances spinal fusion procedures.

Latest Patents

Silke Mark holds one patent titled "Pharmaceutical formulation for use in spinal fusion." This patent describes a pharmaceutical formulation that includes a composition for forming a matrix, a kit comprising the composition, and an interbody spinal fusion cage containing the pharmaceutical formulation. The formulation comprises at least two matrix material precursor components that can crosslink to form a matrix under specific conditions. Additionally, it includes a bioactive factor, specifically PTH or a PTH fusion peptide, which is biologically active in stimulating bone formation between vertebrae and supporting spinal fusion.

Career Highlights

Silke Mark is associated with Kuros Biosurgery AG, a company focused on innovative solutions for spinal surgery. Her work at Kuros has been instrumental in advancing the field of spinal fusion, providing new options for patients undergoing these procedures.

Collaborations

Silke has collaborated with notable colleagues such as Jason Schense and Monica Alvisi. Their combined expertise has contributed to the success of their projects and the advancement of spinal fusion technologies.

Conclusion

Silke Mark's contributions to pharmaceutical formulations for spinal fusion represent a significant advancement in medical technology. Her innovative approach and collaboration with esteemed colleagues continue to impact the field positively.